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Abstract
The Genetic Analysis Workshop (GAW) 16 Problem 3 comprises simulated phenotypes emulating
the lipid domain and its contribution to cardiovascular disease risk. For each replication there were
6,476 subjects in families from the Framingham Heart Study (FHS), with their actual genotypes for
Affymetrix 550 k single-nucleotide polymorphisms (SNPs) and simulated phenotypes. Phenotypes
are simulated at three visits, 10 years apart. There are up to 6 “major” genes influencing variation in
high- and low-density lipoprotein cholesterol (HDL, LDL), and triglycerides (TG), and 1,000
“polygenes” simulated for each trait. Some polygenes have pleiotropic effects. The locus-specific
heritabilities of the major genes range from 0.1 to 1.0%, under additive, dominant, or overdominant
modes of inheritance. The locus-specific effects of the polygenes ranged from 0.002 to 0.15%, with
effect sizes selected from negative exponential distributions. All polygenes act independently and
have additive effects. Individuals in the LDL upper tail were designated medicated. Subjects
medicated increased across visits at 2%, 5%, and 15%. Coronary artery calcification (CAC) was
simulated using age, lipid levels, and CAC-specific polymorphisms. The risk of myocardial infarction
before each visit was determined by CAC and its interactions with smoking and two genetic loci.
Smoking was simulated to be commensurate with rates reported by the Centers for Disease
Control. Two hundred replications were simulated.
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The Framingham Heart Study (FHS) is a rich platform
for the study of cardiovascular disease and the applica-
tion of novel, imaginative analytic strategies. For Genetic
Analysis Workshop (GAW) 16, we use a semi-simulated
approach using actual genotypes from the 500 k
Affymetrix platform and the 50 k candidate gene chip
and building phenotypes on the observed genetic
variation. Because blood lipid levels are a major risk
factor in the development of cardiovascular disease [1],
we modeled disease risk on the lipid pathway, including
both genetic and environmental determinants. The FHS
has reported that long-term averages of low-density
lipoprotein (LDL), high-density lipoprotein (HDL), and
triglyceride (TG) levels were highly heritable (0.66, 0.69,
and 0.58, respectively) [2]. Several familial studies also
have reported heritabilities for LDL of 0.50, HDL of 0.54,
and TG of 0.39 [3]. Dyslipidemia, as a fundamental
component of the atherosclerotic process, is a medically
correctable risk factor with established efficacious treat-
ments for reducing risk of coronary heart disease [4].
Thus, we included in our simulation the use and effects
of dyslipidemic medications, which have an important
role in shaping lipid profiles. This simulation builds in
the long tradition of previous simulations for Genetic
Analysis Workshops [5,6].
Methods
The FHS pedigrees, distributed as GAW16 Problem 2,
formed the basis of our simulation [7]. In total, there
were 6,476 subjects who had genotypes and simulated
phenotypes. After the simulations began, additional FHS
subjects provided broad consent for data sharing; these
additional subjects were not included in the simulations.
To ensure comparable data to that which was simulated,
we provided a file that defined precisely which subjects
were included and their relationships within families.
The ~550 k measured single-nucleotide polymorphism
(SNP) genotypes, distributed for GAW16 Problem 2
from both the genome-wide scan and the additional
candidate gene platform (GeneChip® Human Mapping
500 k Array Set (Nsp and Sty), and the 50 k Human Gene
Focused Panel) comprised the genotypes for GAW16
Problem 3. Novel fictitious phenotypes were simulated
for subjects.
Although family members of the FHS attended various
exams at different times, depending on the generation,
we modeled our study as if all subjects were recruited at
one time, calculated the family member’s relative ages at
one particular exam, and then assigned a simulated age
for everyone at three time points, with 10-year intervals.
The mean age in years (range) for the simulation, by
generation and visit, is shown in Table 1.
The simulation model is depicted in Figure 1. There are
up to six “major” genes for the lipid phenotypes HDL,
LDL, and TG, and 1,000 polygenes for each trait.
Several polygenes have pleiotropic effects (i.e., several
of these polygenes affect two or three or trait
combinations simultaneously). The identity and effects
of the major genes are documented in Table 2. The
locus-specific heritabilities of the major genes range
from 0.1-1.0% under additive (AA:AB:BB, 0:0.5:1),
dominant (AA:AB:BB, 1:1:0), or overdominant (AA:
AB:BB, 0:1:0; heterozygotes show higher effect than the
two homozygotes) modes of inheritance, with minor
allele frequencies at least 5%, with one exception (b4),
for which the minor allele frequency was 1%. We
simulated an overdominant effect (g1) because there
appears to be evidence supporting this possibility and
this mode of inheritance is rarely, if ever, modeled. The
gene a4 is pleiotropic for HDL and TG and interacts
with b5 in determining LDL (Figure 1). The interaction
accounts for 0.7% of the trait variance, and b5h a sn o
marginal effect on any phenotype. The locus-specific
effects of the polygenes were on average an order of
magnitude smaller, ranging from 0.002-0.15%, with
effect sizes extracted from negative exponential dis-
tributions. All polygenes act independently and have
additive effects. HDL, TG, and LDL share 40% of their
polygenes in common, and HDL and TG share an
additional 20%. The specific identities of the poly-
genes, their locations, and their generating effect sizes
are provided in the Additional Files 1, 2, 3 correspond-
i n gt oH D L ,L D L ,a n dT G .Ag r o u po f3 9p o l y g e n e s
influencing HDL were clustered within 0.5 Mb on
chromosome 11; otherwise, the polygenes for each trait
are randomly distributed throughout the genome. The
overall effect of each trait-specific polygenic component
was scaled to achieve the target total trait heritabilities
of 60%, 55%, and 40% for HDL, LDL, and TG,
respectively. The remaining variance is uncorrelated
among family members, with the exception of a
simulated dietary effect (variable: diet) on TG levels
that accounts for a correlation of 0.05 among family
members, regardless of their coefficient of relationship.
The phenotypes generated from this genetic model were
scaled to the empirically derived means and variances
Table 1: Mean ages of the simulated data (mean, minimum, and
maximum age in years)
Mean age (minimum, maximum)
Generation Visit 1 Visit 2 Visit 3
1 66 (54, 80) 76 (64, 90) 86 (74, 100)
2 56 (20, 80) 66 (30, 90) 76 (40, 100)
3 33 (19, 70) 43 (29,80) 53 (39,90)
Overall 43 (19, 80) 53 (29, 90) 63 (39, 100)
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strata (in 5-year intervals) and sex as follows:
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where, for example, ˆ μ (HDL|age 5 year interval, sex) repre-
sents the mean of HDL in FHS, given a 5-year age
interval and sex; ˆ σ (HDL|age 5 year interval, sex) is standard
deviation of HDL in FHS, given a 5-year age interval and
sex; ha1 is the square root of simulated heritability for
the a1 SNP (as described in Table 2); aa1 is a simulated
effect that reflects in part the penetrance of the a1 SNP;
sign is a random integer number that takes values (-1) or
(+1) with the purpose of randomly changing the
contribution direction of polygenes; apoly represents
an instance of each of the 1,000 SNPs effects (k =1t o
1,000), selected as polygenes for HDL; hapoly is an
instance of the of square roots of heritabilities for 1,000
SNPs selected as polygenes for HDL; aε represents the
environmental effect that contributes to HDL; and hε is
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Figure 1
The Genetic Analysis Workshop 16 Problem 3 diagram. Figure 1 shows simulated phenotypes emulating the lipid
domain (HDL, LDL, TG, and CHOL) and its contribution to cardiovascular disease risk (CAC and MI). Simulated major genes
are symbolized with Greek letters. There are 1,000 polygenes for each trait HDL, LDL, and TG, several of them with
pleiotropic effects. Continued lines and arrows show causality/interaction (I); dashed lines show pharmacogenetic effects only
for subjects treated with medication, where response was dependent on the subjects’ genotypes. Environmental factors such
as diet, smoking, and medication were modeled in the simulation.
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mental causes.
As individuals progressed to the next visit 10 years later,
their phenotypes were scaled by the appropriate age-sex
means and variance, but there are no genes governing
longitudinal trends per se. Instead, we simulated the
complicating effects of medication. The simulated value
for LDL at each visit for each subject was checked, and
individuals in the upper tail of the distribution were
s i m u l a t e da sm e d i c a t e d .T h ep r o p o r t i o no fs u b j e c t st h a t
are medicated increased across visits to comprise 2%,
5%, and 15% of the subjects in Visits 1, 2, and 3,
respectively. These proportions were estimated from the
FHS data, and reflected the secular increase in the
proportion of individuals being treated for elevated
cholesterol levels. The response to treatment is governed
by two loci (δ1a n dδ2) as pharmacogenetic processes.
Table 2: Summary characteristics of the major genes and polygenes for traits HDL, LDL, and TG
a
No. Trait Chr Symbol
b Gene SNP Role Total h
2 Model
c MAF h
2 of polygenes
1 HDL 9q31.1 a1 ABCA1 rs10820738 Intron/Exon
boundary
0.010 DOM 6.7
2 HDL 19q13.2 a2 CYP2B7P1 rs8103444 Exon/Intron
boundary
0.002 ADD 24.4
3 HDL 15q21 a3 LIPC rs8035006 Intron 0.003 ADD 32.5
4 HDL 8p22 a4 LPL rs3200218 Exon
downstream
0.003 DOM 21.7
5 HDL 19q13.2 δ1 CYP2B6 rs8192719 Exon/Intron
boundary (Rx)
0.003 ADD
(up 10%)
d
24.9
Total 0.021
6 HDL 1,000 SNPs [apoly] 0.58 ADD ≠ min = 0.0003;
max = 0.0015;
avg = 0.00058
Total 0.60
1 LDL 4p16.3 b1 LRPAP1 rs7672287 Intron 0.003 ADD 22.2
2 LDL 12q13 b2 LRP1 rs1466535 Intron 0.002 ADD 31.6
3 LDL 11q13.4 b3 LRP5 rs901824 Intron/Exon
boundary
0.001 ADD 10.3
4L D L c h r o m 1 b4 rs10910457 0.005 ADD 1.0
5 LDL 8p22 × 4q24 b5 LPL × NFKB1 rs4648068 Intron 0.007 INT 31.0
6 LDL 22q12.2 δ2 SLC5A4 rs2294207 Intron (Rx) 0.010 ADD (down 30%) 25.7
Total 0.028
7 LDL 1,000 SNPs [bpoly] 0.52 ADD ≠ min = 0.0003;
max = 0.00128;
avg = 0.00052
Total 0.55
1 TG 11q23 g1 APOA5 rs603446 Downstream 0.003 OVERD 43.3
2 TG 8p22 a4 LPL rs3200218 Exon
downstream
0.004 ADD 21.7
3 TG 19q13.2 δ1 CYP2B6 rs8192719 Exon/Intron
boundary (Rx)
0.003 ADD (down 15%) 24.9
4 TG diet 0.01 Familial
Total 0.020
5 TG 1,000 SNPs [gpoly] 0.38 ADD ≠ min = 0.0002;
max = 0.0009;
avg = 0.00038
Total 0.40
aAbbreviations: MAF, Minor allele frequency; min, minimum; max, maximum; avg, average; h
2, heritability; [apoly], a vector of 1,000 polygenes that
contribute to HDL; [bpoly], a vector of 1,000 polygenes that contribute to LDL; [gpoly], a vector of 1,000 polygenes that contribute to TG.
bSymbol represents a locus/a vector of polygenes marked by SNPs and corresponding genes, which can be introns/exons, or a diet effect.
cEffects of genes were simulated based on ADDitive (0, 0.5, 1), DOMinant (1, 1, 0), OVERDominant (0, 1, 0), and INTeraction genetic models.
dMedication treatment lowered LDL on a varying percentage of participants dependent on visits: 2% of subjects in Visit 1, 5% of subjects in Visit 2, and
15% of subjects in Visit 3. Medication treatment increased HDL 10%, lowered LDL 30%, and lowered TG 15% for the treated subjects and in
accordance with specific types of genotypes, shown in the “Model” column. For HDL on chromosome 11, 39 SNPs were simulated as a block of
polygenes, starting at 110 Mbp and ending at 134 Mbp, with approximately an average equidistance of 0.5 Mbp.
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levels via additive effects but also, individuals that are
homozygous for the minor allele are non-responders to
the treatment. Responders (homozygotes and hetero-
zygotes for the major allele) exhibit a 10% increase in
their HDL levels and a 15% decrease in TG levels.
Similarly, δ2 is a variant with an additive marginal effect
on LDL, and homozygotes for the minor allele are non-
responders to treatment. Responders exhibit a 30%
decrease in LDL levels. Total cholesterol (CHOL) level
is calculated as 0.8*(HDL + LDL + TG/5), and has no
independent genetic effects except those influencing the
component phenotypes.
Coronary artery calcification (CAC) was simulated as a
quantitative phenotype that takes many years to develop.
For this reason, CAC was modeled in two stages. First,
age-independent CAC (CACAI)w a sm o d e l e da sa
function of total CHOL, HDL, and five other genes
(τ1-τ5) having direct effects on its development. CACAI
was simulated under the model
CAC 5 2 Total CHOL 2 25 HDL 53 AI =+ − () − () ++ ++ 00 0 00 – , ME PE Het ε
where ME is a joint genetic effect from an epistatic
interaction between τ1a n dτ2, the effect of τ1 is purely
epistatic (i.e., τ1 displays only a minimal main effect)
while τ2 displays an additional measurable additive
main effect; PE is the joint effect from τ3a n dτ4, a pair of
purely epistatic SNPs, each with no main effect; Het is an
effect from τ5, a SNP that displays heterosis (over-
dominance); and ε is the residual variation not explained
by the factors mentioned above. The term ε,3 0 0t i m e sa
random draw from a normal distribution with mean 0
and variance 1 (300 × N(0,1)), represents the sum of
normal deviations from the mean of each of the
modeled genetic effects and “noise” from unmeasured
environmental and genetic effects. Because CAC cannot
be negative, CACAI =0i ft h eg e n e r a t e dv a l u ew a s
negative. The models for the effects on CACAI due to the
ME and PE genotypes are illustrated in Tables 3 and 4.
The minor allele frequency (MAF) for each of the four
SNPs τ1-τ4i s~ 0 . 5 .S N Pτ5, which determines the Het
effect, has a MAF of 0.2. SNP τ5 genotype 1/1 (common
homozygote) increases CACAI on average by 25, geno-
type 1/3 decreases CACAI by 100, and genotype 3/3
increases CACAI by 400. CAC is derived from CACAI by
using a piecewise linear age adjustment: subjects under
20 years have not developed measurable levels of CAC,
CAC buildup is linear from the ages of 20 to 60, and for
subjects older than 60, CAC = CACAI. Table 5 lists
estimates of the proportion of the variability of CAC
attributable to each of the genetic factors averaged over
the 200 replicate datasets.
Whether a subject smoked during the period before a
visit influenced the risk of a myocardial infarction (MI).
At first visit, men had a 27% chance to be smokers and
women had a 23% chance. Each smoker had an 8%
chance of permanently quitting smoking before each
subsequent visit. The resulting smoking rates are
commensurate with rates reported by the Centers for
D i s e a s eC o n t r o lf o r1 9 9 8 .T h er i s ko fa nM Ib e f o r ee a c h
visit is determined by CAC and its interactions with
smoking and two genetic loci, 1a n d2. No MIs were
fatal in our data. Smoking and 1 have an interactive
effect on risk of MI. The effect of smoking is to constrict
blood vessels, thus increasing the risk that CAC will lead
to an MI. The risk of MI for a smoker with the most
common 1g e n o t y p e( 3 / 3 )i st h es a m ea st h a to fa n
equivalent non-smoker whose CAC is 10% higher. The
risk of MI for a smoker with either of the other 1
genotypes is the same as that of a non-smoker whose
CAC is 40% higher. The 1 genotype has no effect on
risk of MI in non-smokers. Carrying the most common
2 genotype (3/3) has the same effect on risk of MI as
reducing CAC by 5%. The effect of any other genotype is
the same as increasing CAC by 5%. The final model for
MI risk is
MI risk CAC event smoke _ [ exp( ( . ( )] , =+ − × ×+ +
− 12 4 0 0 2 1
1 ∂
where ∂smoke is the joint effect of smoking and 1( 0i fa
non-smoker, 0.1 if a smoker with genotype 3/3 at 1, 0.4
if a smoker with another genotype); and the value of the
event variable is -0.05 if the 2 genotype is 3/3 and 0.05
otherwise. The MAFs for 1a n d2 are ~0.3. MI_risk was
calculated for each visit and a draw from a uniform
distribution determined whether the risk resulted in an
MI. The SNPs for CAC and MI event were chosen from
Table 3: Mean effects of ME (τ1a n dτ2) on CACAI
τ2
2/2 2/4 4/4 marginal affects
τ12 / 2 - 250 0 250 0
2/4 150 0 - 150 0
4/4 - 250 0 250 0
marginal affects - 100 0 100
Table 4: Mean effects of PE (τ3a n dτ4) on CACAI
τ4
1/1 1/2 2/2
τ32 / 2 200 - 200 200
2/4 - 200 200 - 200
4/4 200 - 200 200
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desired MAF, completeness of genotyping, and lack of
linkage disequilibrium between the SNPs. The specific
identities of the SNPs τ1-τ5, 1a n d2, and their
chromosomes are listed in Table 6.
Results and discussion
The phenotypic simulated files are named simphen#.txt,
where # stands for a number from 1-200, representing
the replication number. The simulated data are archived
in the dbGAP of the National Center for Biotechnology
Information under the name “GAW16 Framingham and
Simulated Data” [8]. The 200 replications of the data
include the indexing variable “shareid” that matches
exactly with the same shareid of the Framingham Heart
Study and can be used to merge the simulated
phenotypic data with the FHS genotypic data. The
phenotypic variables provided are sex, simage (simula-
tion age), diet, rx (antihyperlipidemic medication use),
LDL, HDL, TG, CHOL, CAC, SMOKE, and MIevent, each
associated with a number (1, 2, or 3) to identify
respectively variables that were simulated for Visit 1,
Visit 2, or Visit 3.
We tested all the simulated traits and causative SNP
heritabilities as well as the respective association models.
Analyzing and interpreting data obtained as part of a
genome-wide association study presents numerous
challenges, as well as the promise of improved under-
standing of the genetic factors influencing complex traits.
For validation and a detailed analysis of the simulated
model see the Online Supplemental Materials for
GAW16 [9]. Many genome-wide association studies
have been published recently, and many more are
being carried out on virtually every conceivable pheno-
type of biomedical or public health importance. While
the rate of development of genetic technologies has
propelled us to this point, development and evaluation
of statistical and analytic techniques is still underway,
with many issues not yet satisfactorily resolved. None-
theless, important discoveries have been reported. We
hope that the simulated GAW16 Problem 3 provides
data with which investigators can test the strengths and
limitations of their statistical analytic approaches and
software.
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Table 6: SNPs contributing to CAC and MI event
Trait Factor RS number MAF Chr
CAC τ1 rs6743961 0.4997 2
τ2 rs17714718 0.5000 19
τ3 rs1894638 0.4990 6
τ4 rs1919811 0.4994 7
τ5 rs213952 0.2000 7
MI 1 rs12565497 0.3001 1
2 rs11927551 0.2999 3
Table 5: Proportion of explained variability for the genetic factors contributing to CAC
a (by visit)
Factor L1
b L2
Factor Visit Mean (Min - Max) Mean (Min - Max) Mean (Min - Max)
ME 1 0.0053 0.0037 - 0.0065 0.00002 0.0
c - 0.00012 0.00030 0.00008 - 0.00063
2 0.0092 0.0075 - 0.0112 0.00003 0.0 - 0.00013 0.00055 0.00015 - 0.00093
3 0.0115 0.0091 - 0.0137 0.00003 0.0 - 0.00019 0.00066 0.00027 - 0.00127
PE 1 0.0091 0.0076 - 0.0115 0.00004 0.0 - 0.00020 0.00003 0.0 - 0.00014
2 0.0176 0.0152 - 0.0212 0.00004 0.0 - 0.00017 0.00004 0.0 - 0.00019
3 0.0226 0.0191 - 0.0266 0.00004 0.0 - 0.00021 0.00004 0.0 - 0.00016
Het 1 0.0021 0.0012 - 0.0032
2 0.0045 0.0032 - 0.0060
3 0.0062 0.0045 - 0.0080
aModels included the genetic factors age, sex, CHOL, and HDL.
bColumns L1 and L2 indicate the effect of each of the epistatic loci when analyzed without its mate.
c0.0 indicates R
2<10
-5.
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Additional file 1
Heritability targets and other characteristics for each polygene affecting
HDL.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1753-
6561-3-S7-S4-S1.xls]
Additional file 2
Heritability targets and other characteristics for each polygene affecting
LDL.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1753-
6561-3-S7-S4-S2.xls]
Additional file 3
Heritability targets and other characteristics for each polygene affecting
TG.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1753-
6561-3-S7-S4-S3.xls]
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